Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Finished Goods (2023 - 2025)

Tg Therapeutics has reported Finished Goods over the past 3 years, most recently at $21.1 million for Q3 2025.

  • Quarterly results put Finished Goods at $21.1 million for Q3 2025, up 164.86% from a year ago — trailing twelve months through Sep 2025 was $21.1 million (up 164.86% YoY), and the annual figure for FY2024 was $13.9 million, up 597.25%.
  • Finished Goods for Q3 2025 was $21.1 million at Tg Therapeutics, down from $21.8 million in the prior quarter.
  • Over the last five years, Finished Goods for TGTX hit a ceiling of $21.8 million in Q2 2025 and a floor of $52000.0 in Q1 2023.
  • Median Finished Goods over the past 3 years was $2.0 million (2023), compared with a mean of $7.5 million.
  • Peak annual rise in Finished Goods hit 3559.62% in 2024, while the deepest fall reached 145.07% in 2024.
  • Tg Therapeutics' Finished Goods stood at $2.0 million in 2023, then surged by 597.25% to $13.9 million in 2024, then skyrocketed by 51.3% to $21.1 million in 2025.
  • The last three reported values for Finished Goods were $21.1 million (Q3 2025), $21.8 million (Q2 2025), and $10.7 million (Q1 2025) per Business Quant data.